Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Mbx Biosciences Inc (MBX)

Mbx Biosciences Inc (MBX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth GlobeNewswire - Mon Jul 13, 3:15PM CDT

CARMEL, Ind. and BURLINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...

MBX : 59.55 (-2.85%)
MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism GlobeNewswire - Fri Jun 12, 6:00AM CDT

Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™ trial Results consistent with restoration of systemic PTH activity through serum calcium...

MBX : 59.55 (-2.85%)
MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026 GlobeNewswire - Mon Jun 1, 7:00AM CDT

CARMEL, Ind., June 01, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision...

MBX : 59.55 (-2.85%)
MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City GlobeNewswire - Tue May 26, 7:00AM CDT

CARMEL, Ind. and BURLINGTON, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...

MBX : 59.55 (-2.85%)
MarketBeat.com
MBX Biosciences Obesity Day Spotlights Monthly GLP-1 Hope and Pipeline Push MarketBeat - Mon May 11, 2:09PM CDT

MBX Biosciences (NASDAQ:MBX) used its Obesity Day event to outline preliminary clinical data for its lead obesity candidate MBX 4291, introduce a new preclinical obesity program and reiterate key development...

MBX : 59.55 (-2.85%)
MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing GlobeNewswire - Mon May 11, 6:00AM CDT

Preliminary blinded data from ongoing Phase 1 trial demonstrated mean weight loss of 7% (range 0-16%) at 8 weeks in first MAD Part B cohort (n=8, including 2 placebo) MBX 4291 generally well tolerated,...

MBX : 59.55 (-2.85%)
MBX Biosciences: Can Platform Validation Wait Until Late 2026 Without a Differentiation Problem? Barchart - Fri May 8, 4:08PM CDT

Barchart Research What to Expect from MBX Earnings MBX Generated May 8, 2026 Current Price $40.97 EPS Estimate $$-0.68 Consensus Rating Strong Buy Average Move 4.47% MBX Biosciences: Can Platform Validation...

MBX : 59.55 (-2.85%)
MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights GlobeNewswire - Thu May 7, 7:00AM CDT

Results from Phase 2 trial of once-weekly canvuparatide accepted for oral presentation at ENDO in June 2026 Phase 3 trial of once-weekly canvuparatide on track to initiate in Q3 2026 Appointment...

MBX : 59.55 (-2.85%)
MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award GlobeNewswire - Thu May 7, 6:00AM CDT

CARMEL, Ind. and BURLINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...

MBX : 59.55 (-2.85%)
MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio GlobeNewswire - Thu Apr 23, 7:00AM CDT

CARMEL, Ind. and BURLINGTON, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...

MBX : 59.55 (-2.85%)

Barchart Exclusives

A $1 Billion Reason to Buy Naver Stock Now Barchart - 4 minutes ago
The investment is for the expansion of an AI factory in South Korea. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.